HOME >> MEDICINE >> NEWS
Millions wasted on blood pressure tablets

Millions of dollars are being spent unnecessarily each year on treatments for high blood pressure says research published this week in BMC Health Services Research. Vast amounts could be saved if doctors prescribed thiazides, the recommended and cheapest drugs, rather than expensive alternatives.

Atle Fretheim and his colleagues from the Norwegian Directorate for Health and Social Affairs estimated the potential annual savings for six countries if thiazides were prescribed whenever there was no reason to use an alternative. The savings could be huge: Canada - US$13.8m, France - US$37.4m, Germany - US$72.2m, Norway - US$10.7m, UK - US$119.7m and US - US$433.6m.

"Our calculations are based on conservative estimates. The potential for saving is likely to be considerably higher, and may be over US$1billion per year in the US," write the researchers.

To produce these estimates, the researchers used sales, prescription and survey data to estimate the number of people in each country that were being treated for high blood pressure, and the proportion of those that were taking thiazides. The proportion varied between countries from 12% to 40%. Previously published research suggests that thiazides could be used effectively in at least 45% of all cases. Armed with this information, the researchers worked out the potential annual cost savings to health services. They calculated the costs of increasing thiazide usage to its limit, and the resulting cost reductions of other treatments, assuming these reductions would be distributed evenly across those treatments.

All clinical guidelines recommend thiazides as a first choice drug for treating uncomplicated high blood pressure. This is because no drug to treat high blood pressure has been identified as being clearly superior to the others, and the evidence that thiazides reduce the risk of stroke and heart disease is strong. Thiazides are also amongst the best tolerated drugs, and are by far
'"/>

Contact: Gemma Bradley
press@biomedcentral.com
44-207-323-0323
BioMed Central
7-Sep-2003


Page: 1 2

Related medicine news :

1. Millions who suffer from nut and milk allergies could benefit from Stanford researchers test
2. Millions of Asian Americans and Pacific Islanders at increased risk for type 2 diabetes
3. Millions turn a blind eye to dangerous driving
4. Millions of Americans are failing to get recommended health care
5. Millions of migraine sufferers could benefit from better use of medical care
6. Millions Of Americans With Glaucoma Could Save Sight With Early Detection, Treatment
7. Engineering Study For The CDC Shows How To Fight Low Childhood Immunization,Save Millions In Health Costs
8. A marker for new blood vessel formation in tumors
9. Acupuncture found to lower elevations in blood pressure
10. Diagnostic test for range of blood disorders on the horizon
11. Research suggests possible blood test for multiple sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Millions wasted blood pressure tablets

(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 ... senior care, today announces the launch of the ... innovative senior care stakeholders and technology companies. The announcement ... Center (NIC) Capital and Business Strategies Forum in ... members, the new Alliance program is now open for ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , Dallas ... Department of Plastic Surgery at UT Southwestern Medical Center, ... blindness resulting from the use of facial aesthetic ... study, along with ideas for treatment and prevention in ... to see increasing reports of blindness as a result ...
(Date:4/1/2015)... GA (PRWEB) April 01, 2015 ... Medicine Practice, Pediatric Emergency Medicine Practice, and Hospital ... has partnered with AgileMD to provide the content ... , in a mobile application format available on ... , “Our collaboration with AgileMD to develop mobile ...
(Date:4/1/2015)... 2015 Skin cancer is one of the ... caught early. Forefront Dermatology and Dermatology Associates of Wisconsin want ... before it spreads so they are hosting a free skin ... 8:30am - 12:30pm. , “If we can see the ... concern, that could become cancerous,” said Dr. Ken Katz, who ...
Breaking Medicine News(10 mins):Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kz78wm/medical_device ) ... Device Studies: Clinical Evidence" conference to their ... specifically for those who are involved in gathering ... diagnostic products. Clinical data is required for all ... appropriate clinical evidence has grown substantially in the ...
(Date:4/1/2015)... Md. , April 1, 2015  RegeneRx ... today announced that a new medical paper has ... beta 4 (TB4) in patients with severe dry ... the study and the physicians stated that statistically ... severe dry eye were seen at various time ...
(Date:4/1/2015)... LAVAL, Quebec , April 1, ... Inc. (NYSE: VRX and ... completed the previously announced acquisition of ... a specialty pharmaceutical company that offers ...  (rifaximin) 550 mg, RUCONEST ®  (C1 esterase inhibitor ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
Cached News: